Developing first-in-class medicines
Using synthetic lethality strategy, SynRx Therapeutics is developing novel anti-cancer agents. Several first-in-class compounds are currently in preclinical studies.
Founder
Xiaochun Yu
Professor,Founder and Chairman
Professor, University of Michigan Medical School
M.D.,Beijing Medical University
Ph.D., Kurume University, Japan
Published more than 100 academic papers
/
